(Q37764869)

22 August 2017

1 reference

title

Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options (English)

1 reference

chronic lymphocytic leukemia

22 August 2017

0 references

1 reference

1 reference

2

Michael J Keating

1 reference

PubMed ID

20545582

Apostolia Maria Tsimberidou

22 August 2017

series ordinal

1

object named as

Apostolia-Maria Tsimberidou

1 reference

22 August 2017

1 July 2010

1 reference

22 August 2017

1 reference

22 August 2017

51

1 reference

22 August 2017

7

1 reference

22 August 2017

1188-1199

1 reference

22 August 2017

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Chronic lymphocytic leukemia (CLL): first-line treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Recent progress in the management of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Twenty years of p53 research: structural and functional aspects of the p53 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

The role of fludarabine in hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients wit

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Disease-specific complications of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia: a phase II SWOG TRIAL 9706.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Rituximab dose-escalation trial in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Role of auto- and allotransplantation in B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.486089

10.3109/10428194.2010.486089

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20545582